Native HIV-1 Tat protein targets monocyte-derived dendritic cells and enhances their maturation, function, and antigen-specific T cell responses

Journal of Immunology

Volumn 168, Issue 1, 2002, Pages 197-206

  Fanales Belasio, E ^a   Moretti, S ^a   Nappi, F ^a   Barillari, G ^a   Micheletti, F ^a   Cafaro, A ^a   Ensoli, B ^a  

^a ISTITUTO SUPERIORE DI SANITÀ   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE; DNA VACCINE; INTERLEUKIN 12; MAJOR HISTOCOMPATIBILITY ANTIGEN; TRANSACTIVATOR PROTEIN; TUMOR NECROSIS FACTOR ALPHA;

ANTIGEN PRESENTATION; ANTIGEN PRESENTING CELL; ANTIGEN SPECIFICITY; ARTICLE; CELL FUNCTION; CELL MATURATION; CONTROLLED STUDY; DENDRITIC CELL; ENDOCYTOSIS; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNE RESPONSE; IMMUNOSTIMULATION; MONKEY; OXIDATION; PRIORITY JOURNAL; PROTEIN TRANSPORT; TH1 CELL;

EID: 0036136322     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.168.1.197     Document Type: Article

References (53)

1. The trans-activator gene of human T-lymphotropic virus type III (HTLV-III)
2. The trans-activator gene of HTLV-III is essential for virus replication
3. Regulation of cellular gene expression and function by the human immunodeficiency virus type 1 Tat protein
4. Cellular uptake of the Tat protein from human immunodeficiency virus
5. Tat protein of HIV-1 stimulates growth of cells derived from Kaposi's sarcoma lesions of AIDS patients
6. Effects of cytokines from activated immune cells on vascular cell growth and HIV-1 gene expression: Implications for AIDS-Kaposi's sarcoma pathogenesis
7. Release, uptake, and effects of extracellular human immunodeficiency virus type I Tat protein on cell growth and viral transactivation
8. HIV-1 Tat protein exits from cells via a leaderless secretory pathway and binds to extracellular matrix-associated heparan sulfate proteoglycans through its basic region
9. Tat protein induces human immunodeficiency virus type 1 (HIV-1) coreceptors and promotes infection with both macrophage-tropic and T-lymphotropic HIV-1 strains
10. + T cells
11. Speed of progression to AIDS and degree of antibody response to accessory gene products of HIV-1
12. A (SIV) proteins in SIV-infected macaques
13. Epitopes for natural antibodies of human immunodeficiency virus (HIV)-negative (normal) and HIV-positive sera are coincident with two key functional sequences of HIV Tat protein
14. Cytotoxic T lymphocyte activity in children infected with HIV
15. Effect of antibody to HIV-1 Tat protein on viral replication in vitro and progression of HIV-1 disease in vivo
16. Human immunodeficiency virus type I Rev- and Tat-specific cytotoxic T lymphocyte frequencies inversely correlate with rapid progression to AIDS
17. Antibodies to the HIV-1 Tat protein correlated with nonprogression to AIDS: A rationale for the use of Tat toxoid as an HIV-1 vaccine
18. The HIV-1 regulatory proteins Tat and Rev are frequently targeted by cytotoxic T lymphocytes derived from HIV-1-infected individuals
19. Tat-specific cytotoxic T lymphocytes select for SIV escape variants during resolution of primary viraemia
20. Control of SHIV-89.6P-infection of cynomolgus monkeys by HIV-1 Tat protein vaccine
21. SHIV89.6P pathogenicity in cynomolgus monkeys and control of viral replication and disease onset by human immunodeficiency virus type 1 Tat vaccine
22. Vaccination with DNA containing tat coding sequences and unmethylated CpG motifs protects cynomolgus monkeys upon infection with simian/human immunodeficiency virus (SHIV89.6P)
23. Vaccination with Rev and Tat against AIDS
24. Minimization of chronic plasma viremia in rhesus macaques immunized with synthetic HIV-1 Tat peptides and infected with a chimeric simian/human immunodeficiency virus (SHIV33)
25. Vaccination with tat toxoid attenuates disease in simian/HIV-challenged macaques
26. Tat-mediated delivery of heterologous proteins into cells
27. Tat-mediated protein delivery can facilitate MHC class I presentation of antigens
28. Introduction of soluble proteins into the MHC class I pathway by conjugation to an HIV tat peptide
29. Trojan peptides: The penetratin system for intracellular delivery
30. Dendritic cells and the control of immunity
31. Dendritic cells
32. 3 integrins by mobilizing sequestered basic fibroblast growth factor
33. 3 integrin that are required for Tat activity
34. A quantitative bioassay for HIV-1 based on trans-activation
35. Synergy between basic fibroblast growth factor and HIV-1 Tat protein in induction of Kaposi's sarcoma
36. Antibodies against sialophorin (CD43) enhance the capacity of dendritic cells to cluster and activate T lymphocytes
37. Selective amino acid substitutions of a subdominant Epstein-Barr virus LMP2-derived epitope increase HLA/peptide complex stability and immunogenicity: Implications for immunotherapy of Epstein-Barr virus-associated malignancies
38. The Th1/Th2 paradigm
39. Lymphocyte traffic control by chemokines
40. Transient exposure to HIV-1 Tat protein results in cytokine production in macrophages and astrocytes: A hit and run phenomenon
41. The Tat protein of human immunodeficiency virus type 1, a growth factor for AIDS Kaposi sarcoma and cytokine-activated vascular cells, induces adhesion of the same cell types by using integrin receptors recognizing the RGD amino acid sequence
42. Internalization of HIV-1 tat requires cell surface heparan sulfate proteoglycans
43. 3 integrin and requires intracellular and extracellular calcium
44. The RGD-containing domain of exogenous HIV-1 Tat inhibits the engulfment of apoptotic bodies by dendritic cells
45. HIV-1-Tat protein promotes chemotaxis and invasive behavior by monocytes
46. HIV-1-Tat modulates the function of monocytes and alters their interactions with microvessel endothelial cells: A mechanism of HIV pathogenesis
47. Activation of monocytes by HIV-Tat treatment is mediated by cytokine expression
48. Inhibition of antigen-induced lymphocyte proliferation by Tat protein from HIV-1
49. Interferon α and Tat involvement in the immunosuppression of uninfected T cells and C-C chemokine decline in AIDS
50. Pronounced acute immunosuppression in vivo mediated by HIV Tat challenge
51. Tat as one key to HIV-induced immune pathogenesis and Tat (correction of Pat) toxoid as an important component of a vaccine
52. DNA immunization with HIV-1 tat mutated in the trans activation domain induces humoral and cellular immune responses against wild-type Tat
53. Cellular cytotoxic response induced by DNA vaccination in HIV-1-infected patients